
-
2seventy Bio NasdaqGS:TSVT 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
Location: 60 Binney Street, Cambridge, MA, 02142, United States | Website: https://www.2seventybio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
335.5M
Cash
170.4M
Avg Qtr Burn
-13.52M
Short % of Float
6.08%
Insider Ownership
6.44%
Institutional Own.
82.40%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ABECMA (IDE-CE) (bb2121) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
ABECMA (IDE-CEL) (bb2121) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
bbT369 Details Cancer, Non-Hodgkin lymphoma, B-cell lymphoma | Phase 1 Update | |
SC-DARIC33 Details Cancer, Acute myeloid leukemia, Relapsed/refractory acute myeloid leukemia | Phase 1 Update |